Concepedia

L.R. Silverman

LS

9

Publications

601

Citations

9

H-Index

1999

Active since

Affiliations

Icahn School of Medicine at Mount Sinai(Current)

L.R. Silverman is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, pharmacotherapy, and oncology.

Top concepts

Publications per year

1999–2013

9

Publications

9

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies

Shashi Jatiani, Suzanne J. Baker, L.R. Silverman et al. · Genes & Cancer · 2010 · 223 citations · Full text

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

Steven D. Gore, Pierre Fenaux, Valeria Santini et al. · Haematologica · 2013 · 133 citations · Full text

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Pierre Fenaux, G J Mufti, Valeria Santini et al. · Blood · 2007 · 102 citations

Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

Alan F. List, Pierre Fenaux, G J Mufti et al. · Journal of Clinical Oncology · 2008 · 49 citations

, , +21

A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium

L.R. Silverman, Anupam Verma, Rosalie Odchimar-Reissig et al. · Journal of Clinical Oncology · 2008 · 40 citations

, , +15

Rows per page

1–5 of 9